Rationale: Diagnosis of ventilator-associated pneumonia (VAP) is imprecise.
results. Clinical guidelines (11, 13) advise initiating broad-spectrum therapy at the time a patient presents with symptoms consistent with pneumonia, after a lower respiratory specimen is acquired for microbiological confirmation. Empiric broad-spectrum therapy may fail, with multidrug resistance contributing to risk in approximately 20% of health care-associated infections (9, 14) . Switching therapy from inadequate to adequate antibiotics must, however, occur in less than 1 day to improve outcomes (15) . Prolonged broad-spectrum empiric therapy can also contribute to the selection and spread of multidrug resistant organisms (MDROs) (16, 17) . Rapid deescalation to optimal therapy based on resistance testing (11, 18, 19) is therefore important for antimicrobial stewardship.
A significant proportion of patients may develop a bacterial infection without meeting the criteria for clinical diagnosis despite a substantial microbiological burden (20) . By implication, surveillance to detect clinically cryptic infection could have significant clinical value. However, the usefulness of this approach has not been rigorously evaluated (21) . We therefore conducted a pilot study to test the hypothesis that intermittent microbiological lung surveillance for a panel of potential MDROs in mechanically ventilated intensive care unit (ICU) patients at risk for but in advance of VAP symptoms would shorten the time to initiation of adequate therapy. We additionally hypothesized that compared with conventional culturing methods, analysis of organisms extracted directly from mini-bronchoalveolar lavage (BAL) specimens using a novel, automated microscopy phenotypic testing technique would further reduce time to diagnosis and initiation of adequate antibiotics and guide deescalation to specific therapy.
Some of the data in this study were presented at the American Thoracic Society 2011 International Conference (22) .
Methods
Complete methods may be found in the online supplement.
The Colorado Multiple Institutional Review Board approved the study. Informed consent (from the patient or by surrogate) was obtained.
Patients
Patients were recruited from August 1, 2009 to September 30, 2010 when they were admitted to a 24-bed medical ICU at Denver Health Medical Center (Denver, CO). Patients 18 years of age and older were eligible if the first study procedure could be performed within 72 hours of intubation, and if more than 48 hours of ventilation was anticipated after the first procedure. Patients were excluded for diffuse bronchiectasis, massive hemoptysis, cystic fibrosis, participation in a drug or device trial within 30 days, if pregnant or nursing, had an advanced directive to withhold life support, or were expected to survive less than 14 days.
Baseline demographics were collected including Acute Physiology and Chronic Health Evaluation (APACHE) II and Clinical Pulmonary Infection Score (CPIS). Clinical symptoms of VAP were evaluated daily. Additional process and outcome measures were collected including duration of ventilation, number of mini-BAL procedures, volume of BAL fluid returned, length of ICU stay, adverse events, discharge vital status, and mortality.
Mini-BAL Surveillance
On Days 1, 3, 5, 7, and 10 of ventilation, distal airway specimens were collected by nonbronchoscopic mini-BAL as previously described (23) (see the online supplement). Mini-BAL samples were divided into two aliquots, with one analyzed by routine clinical microbiological culturing and the other with a custom-built automated microscopy instrument.
Clinical Culture Testing and Impact on Prescribing
The hospital laboratory performed semiquantitative microbiological culturing, identification (ID), and antibiotic susceptibility testing (AST) according to standard practices. The hospital laboratory reported data to ICU clinicians to assist medical decision-making. A threshold of at least 10 4 cfu/ml was used to classify specimen content as microbiologically positive or negative. Antibiotics prescribed or changed as a result of mini-BAL culture were collected for patients with positive clinical microbiology cultures. 
Results
Thirty-three patients were enrolled in the study. Patient demographics are summarized in Table 2 . Patients were critically ill (median APACHE II score was 21 (IQR, [16] [17] [18] [19] [20] [21] [22] [23] [24] and the majority had radiological pulmonary infiltrates. Of the 33 patients, one patient (patient 5) was diagnosed with VAP by clinical criteria during study enrollment. Nine adverse events were associated with the surveillance mini-BAL procedure (12%), of which none were considered serious. Bloody lavagate occurred in four cases (5%), desaturation requiring an increase in fraction of inspired oxygen occurred in two cases (3%), agitation within the 60 minutes after the procedure occurred in two cases (3%), and there was one instance of transient sinus tachycardia (1%).
Mini-BAL Surveillance and Safety
Of 77 specimens obtained for analysis, 3 were rejected because of quality issues, and 1 additional specimen could not be analyzed because of a technical failure with the microscopy system. A total of 73 specimens were tested by both microscopy and conventional clinical microbiological cultures.
Clinical Culture Results and Impact on Prescribing
Semiquantitative clinical culture identified 15 samples acquired from 11 patients as microbiologically positive with at least 1 bacterial type at or exceeding 10 4 cfu/ml (21% of 73 specimens, 33% of 33 patients). Eleven (15%) of these samples contained mixed respiratory bacteria and 7 (10%) samples from 5 patients contained respiratory bacterial pathogens: 4 Staphylococcus aureus, 2 Stenotrophomonas maltophilia, and 1 Klebsiella pneumoniae.
Routine culture results were used by clinical staff to guide changes to antimicrobial prescribing for two of five (40%) microbiologically positive patients (Table 4 ). For patient 6, identification of S. maltophilia in the mini-BAL sample taken on Day 1 (6-D1), resulted in initiation of trimethoprim-sulfamethoxazole therapy on Day 3, and subsequent discontinuation of caspofungin, piperacillin-tazobactam, and vancomycin. Levofloxacin therapy initiated on Day 2 was continued on the basis of AST results indicating susceptibility to trimethoprim-sulfamethoxazole and levofloxacin.
For patient 17, identification of K. pneumoniae by conventional culture of Day 1 mini-BAL sample (17-D1) resulted in the initiation of treatment with ceftriaxone and cefazolin on Day 2. AST results indicating susceptibility to both drugs, but available only more than 48 hours after sample acquisition, resulted in discontinuation of ceftriaxone treatment and continuation of cefazolin treatment by Day 3.
Comparison between Clinical Culture and Automated Microscopy Results and Timing
Clinical culture and automated microscopy identification and quantitation results for microbiologically positive samples are summarized in Table 5 . Five of nine samples were polymicrobial, but no sample contained more than one VAP-associated bacterial pathogen. Two patients had positive pathogen isolates by conventional culture and microscopy in more than one specimen. Microscopy-based microbiological quantitation was positive in six of the seven samples that were microbiologically positive by culture (sensitivity, 86%). The single false negative (3-D1) contained S. aureus that grew too slowly in Mueller-Hinton broth but had a high growth rate in fastidious medium. Primary (blinded) analysis did not include images from the fastidious medium. Reanalysis after unblinding including images from the fastidious medium identified S. aureus, resulting in 7 of 7 microbiologically positive samples (sensitivity, 100%) and 64 of 66 microbiologically negative samples (specificity, 97%) ( Figure 1 ). There were two false-positive results including one sample determined to contain an enteric species (5-D7, 1.28 3 10 5 cfu/ml) by microscopy, but that was consistently negative by clinical culture. That patient had an initial CPIS of 3 at the time of specimen collection, but was diagnosed 2 days later with VAP on the basis of clinical criteria. A second false positive occurred in a cultured sample (33-D7) that included Candida and mixed respiratory flora. The clinical laboratory culture report noted "rare" gram-positive cocci on Gram stain. Further analysis by a coagulase assay determined that a coagulase-negative
Staphylococcus organism was present. The microscopy assay detected cocci, but incorrectly identified this organism as S. aureus at a microbiologically positive density (6.64 3 10 4 cfu/ml). These falsepositive results would not have significantly increased the annual ICU VAP rate of 2.8-2.9 cases per 1,000 ventilator days.
AST results were available for comparison with four patient specimens. Microscopy results characterized two specimens containing S. aureus as methicillin-resistant S. aureus (MRSA) phenotypes (8-D7, 22-D3) and two specimens from one patient as amikacinresistant S. maltophilia (6-D1, 6-D3), concordant with culture results. One specimen (8-D7) contained S. aureus classified as clindamycin resistant by microscopy but clindamycin susceptible by culture. D-test confirmed that the specimen did not exhibit inducible clindamycin resistance.
The time to obtain results from hospital clinical microbiology laboratory cultures averaged 31 6 3 hours (SEM) for identification and quantitation and 50 6 7 hours (SEM) for AST (total time elapsed after starting cultures). Time to obtain identification, quantitation, and AST results from microscopy analysis included 1.5 hours of sample preparation plus a 3-hour fixed duration for image acquisition (P , 0.0001 for comparison of total elapsed time). Microscopy times were determined as the interval between the start of specimen processing and final image acquisition (approximately 5 h). Image analysis was performed offline after data collection and was not included in the timing calculation for this study.
Simulated Impact of Automated Microscopy Results on Prescribing
Simulated application of automated microscopy results would have resulted in a change in antimicrobials for three of seven patients (43%) found microbiologically positive by automated microscopy (Table 6) . Microscopy results for specimen 5-D7 (patient 5, Day 7) identified an enteric species (1.28 3 10 5 cfu/ml) that was susceptible to amikacin and imipenem, and resistant to piperacillin-tazobactam. This specimen, however, showed no growth by clinical culture. The patient was not receiving any antibiotics at the time the specimen was collected (Day 7). Two days later (Day 9), the patient was clinically 
Discussion
This prospective single-center cohort study applied two diagnostic methods to analyze lower respiratory tract specimens obtained before VAP clinical diagnosis: standard laboratory culturing with 2-to 3-day turnaround (50 6 7 h), and a novel automated microscopy method that has potential for same-day phenotypic antibiotic susceptibility analysis. The study determined, in mechanically ventilated adults with bilateral pulmonary infiltrates on portable chest X-ray, the frequency of microbiologically positive mini-BAL specimens before a clinical VAP diagnosis. We assessed the attending physician's use of clinically available surveillance culture results in timing and selection of antibiotics. The study also compared time to diagnosis and accuracy for automated microscopy results with standard clinical culture results performed with paired aliquots from a single surveillance mini-BAL specimen. To our knowledge, this is the first clinical assessment of a polymicrobial diagnostic technology potentially capable of same-day quantitative identification and major antibiotic resistance phenotyping directly from mini-BAL specimens.
The clinical microbiological diagnosis of VAP is controversial and risk prediction scoring is of variable value in determining pretest probability of VAP. However, CPIS has previously been evaluated in this type of study, providing a useful benchmark.
Of the 33 patients, 1 patient (patient 5) was diagnosed with VAP by clinical criteria. Microbiologically positive (.10 4 cfu/ml) False-negative microscopy result; organism grew only in flowcell containing fastidious growth media, but S. aureus identification test was not activated in that flowcell. S. aureus was correctly identified when the specimen was analyzed further after unblinding. quantities of VAP-associated bacteria were detected by culture in 5 of the 32 patients (16%) not diagnosed with VAP. Four of these five patients (80%) had a CPIS equal to or greater than 6 but fell short of meeting additional criteria for VAP clinical diagnosis. The fifth patient had a CPIS of 4 despite having a positive pathogen burden. These results indicate that microbiological surveillance can detect potentially lethal asymptomatic infections in settings of low clinical suspicion as proposed by Zhuo and colleagues (20) . A majority of critically ill, mechanically ventilated patients are treated with broad-spectrum antibiotics, even in the absence of proven bacterial infection (11) . In the current study, clinical culture results resulted in changes to empiric antimicrobial prescribing for two of five patients (40%) found to be microbiologically positive for a VAPassociated pathogen but negative for VAP clinical diagnosis. Appropriate therapy was initiated sooner, and ineffective therapy was discontinued in each case. Microbiological surveillance differentiates infection from colonization on the basis of a quantitative criterion, that is, organism specimen density. This information is important not only for initiating antimicrobial treatment in infected patients, but also for optimal antimicrobial stewardship by avoiding inappropriate antimicrobial treatment in patients without pneumonia. Adverse events associated with the surveillance mini-BAL procedure and sample collection were infrequent (9 of 77 mini-BALs, 12%) and were transient in nature, requiring specific therapy (transient increase in fraction of inspired oxygen postprocedure) in few cases. These data support the relative safety of this procedure as previously reported (23) . Bronchial aspirates were not used in this study, as their use may be associated with overdiagnosis of VAP.
In comparison with clinical culture results, pathogen identification by automated microscopy was both sensitive (100%) and specific (97%), according to reanalysis after unblinding. One S. aureus sample (3-D1) grew only on fastidious medium. Although the blinded study phase did not include data from the channel that contained the fastidious medium, reanalysis after unblinding resolved this discordant result. Including data for fastidious media in future studies would detect such organisms. Of the two false positives, one was a coagulase-negative S. aureus that automated microscopy misidentified as S. aureus. Improved identification algorithms could prevent this error in the future by applying appropriate criteria for differential growth rate.
The second false positive was an enteric organism that may have been undercounted by conventional culturing. This patient (patient 5) was diagnosed with VAP 2 days after the specimen was obtained, suggesting that conventional culture was insufficiently sensitive to identify the true etiological pathogen that microscopy detected at microbiologically positive density. Microscopy AST confirmed that the organism was susceptible to amikacin and imipenem.
Post hoc simulations using microscopy results at the end of the 5-hour specimen preparation and data collection period to inform clinical decisions indicated that treatment changes could have been made for three of seven patients found microbiologically positive by automated microscopy. Adequate therapy could have been initiated 2-3 days sooner in each case, and 12 total antimicrobial days of inadequate therapy could have been eliminated for the three culture-positive patients. In addition, in simulation, one could have received targeted antibiotic treatment 2 days sooner than the empiric therapy initiated on clinical diagnosis of VAP. Although these data do not prove a broad necessity for surveillance screening, the usefulness of this approach for early detection of MDRO pathogens in very high-risk patients is of significant potential interest. The current findings are consistent with those of a previous simulation study (24) that used automated microscopy of banked isolates and retrospective chart review for S. aureus infections. That study categorized actual drug choices as inactive, optimal, or suboptimal (excessively broad spectrum or unnecessary), using the patient-care clinical laboratory culture result as the reference. The previous study found a potential reduction of inactive therapy from 27 to 0%; reduction of suboptimal therapy from 26 to 3%; and potential increase of optimal therapy from 46 to 97% after applying the observed analytical accuracy of the automated microscopy system.
The possible clinical benefits of this new rapid diagnostic technique include reducing inappropriate antimicrobial use by decreasing the rate of inadequate antimicrobials shortly after initiation of empirical antibiotics and guiding early and aggressive deescalation. These in turn could potentially result in improved patient outcomes including decreased mortality rates and lengths of stay as well as reduced hospital costs.
One limitation of our study in estimating the potential impact of bacteriological surveillance was the absence of a control arm for the current usual care approach in which cultures are not obtained unless and until a patient meets clinical criteria for VAP diagnosis. However, our study design is consistent with those previously published. Brusselaers and coworkers concluded from a systematic review that sequential lower respiratory tract surveillance cultures to predict bacterial VAP were useful (sensitivity, z0.75; specificity, z0.92 in culture-positive VAP) (25) . However, 13 of the 14 included ORIGINAL ARTICLE studies used only endotracheal aspirates for surveillance. In only one study was nonbronchoscopic, mini-BAL used as one of the strategies for sequential surveillance (26) . Microbiological sensitivity in that study of mini-BAL was only 74% with a specificity of 70%, significantly lower performance characteristics than we found. That study also lacked a usual care arm for comparison.
A second limitation was the use of a custom automated microscopy system and offline analyses performed with expert interpretation assisted by automated growth analysis. These conditions enabled feasibility assessment by means of simulated clinical application. In future studies, the performance of a fully automated system with real-time image analysis will be determined. A fully automated system could be used to prospectively assess the impact of surveillance with same-day microbiological diagnosis on choice of therapy and on surrogate outcome variables. A third limitation was that the simulation method looked only at microbiological data alone to modify treatment decisions rather than taking additional factors into account as would occur in a clinical setting. A fourth limitation was that all specimens were obtained from a single institution. This restriction significantly limited the cumulative number of cases available within the study period. The use of prospective informed consent significantly limited the number of enrolled cases. As a fifth limitation, the small number of positive diagnoses limited the statistical usefulness in assessing the potential value of microbiological surveillance in ICU patients at risk of acquiring VAP. The number of specimens acquired did, however, support the relative safety of using mini-BAL for surveillance.
We conclude that despite these limitations, the usefulness of mini-BAL surveillance and clinical cultures to detect lung infection and inform treatment options is feasible and safe. A significant proportion of surveillance patients did exhibit microbiologically positive pathogen burden before or in the absence of a positive clinical diagnosis. We also conclude that automated microscopy has the potential to further accelerate rapid microbiological diagnosis in patients at risk for VAP and before clinical diagnosis. Earlier availability of identification and AST results obtained through targeted surveillance has the potential to improve clinical outcomes for patients. Early detection and specific antibiotic guidance is also critical for improving antimicrobial stewardship by decreasing the inadequate or suboptimal use of broad-spectrum antibiotic therapy. Future expanded trials using fully automated analysis of automated microscopy results are needed to determine the clinical impact of same-day microbiological diagnostics on treatment optimization and outcomes for emergent VAP. n Author disclosures are available with the text of this article at www.atsjournals.org.
